Cite

HARVARD Citation

    Cai, L. et al. (n.d.). Enhancement of anti-tumor immunity and survival prolongation by neoadjuvant 5-FU, oxaliplatin and irinotecan (folfirinox) in pancreatic ductal adenocarcinoma patients. HPB. pp. S10-. [Online]. 
  
Back to record